|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0700 - 0.1200|
|52 Week Range||0.0200 - 2.7450|
|Beta (5Y Monthly)||-9.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Multiple acquisitions to drive significant growth of customer base LEHI, UT / ACCESSWIRE / February 14, 2020 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology ...
Under the terms of the Agreement, Genecor AI Inc., a Canadian Company, has acquired the International rights (excluding the USA), to Frelii's patent pending AI, Navii for $750,000 payable in installments over 3 months. Through its network of medical professionals, Genecor AI will market Frelii's DNA technology in Canadian market, with plans to expand to other jurisdictions.
LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a Master License Agreement ("Agreement) with Systemic Formulations Inc. ("Customer"). "We believe the efficacy of our genome discovery artificial intelligence, Navii, has been further validated today, as trusted leading nutraceutical company Systemic Formulations has begun selling DNA kits to its network of healthcare practitioners using Navii to provide market leading analysis," stated Frelii CEO, Ian Jenkins.
LEHI, UT / ACCESSWIRE / October 30, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or "the Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update to shareholders regarding technology and marketing advancements. Frelii's CEO, Ian Jenkins stated, "Over the past year, through the diligence of our development team, led by respected industry leader Jayson Uffens, the Company has successfully navigated a variety of challenges, resulting in critical enhancements to our technology offering. The Company utilizes artificial intelligence and whole genome analysis to increase patient outcomes and reduce direct costs.
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective ...